Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Etoricoxib
Therapeutic Area : Rheumatology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy Anda Safety of Etoricoxib With Betamethasone for the Treatment of Acute Gout Arthritis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 07, 2025
Lead Product(s) : Etoricoxib
Therapeutic Area : Rheumatology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Etoricoxib
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 07, 2025
Lead Product(s) : Etoricoxib
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Etoricoxib
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Safety of Etoricoxib/Cyanocobalamin Versus Etoricoxib for Acute Low Back Pain
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 24, 2024
Lead Product(s) : Etoricoxib
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Etoricoxib
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Infinite Clinical Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Safety of Etoricoxib-tramadol Tablet in Acute Postoperative Pain
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 16, 2023
Lead Product(s) : Etoricoxib
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Infinite Clinical Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Etoricoxib
Therapeutic Area : Undisclosed
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 13, 2023
Lead Product(s) : Etoricoxib
Therapeutic Area : Undisclosed
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Etoricoxib
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 08, 2022
Lead Product(s) : Etoricoxib
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Etoricoxib
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Anapharm
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 20, 2021
Lead Product(s) : Etoricoxib
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Anapharm
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Etoricoxib
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 20, 2021
Lead Product(s) : Etoricoxib
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Etoricoxib
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : ClinPharmInvest
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 05, 2021
Lead Product(s) : Etoricoxib
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : ClinPharmInvest
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Etoricoxib
Therapeutic Area : Undisclosed
Study Phase : Undisclosed
Sponsor : Equilab International
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioequivalence Study of 120 mg Etoricoxib Film-coated Tablets
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 05, 2018
Lead Product(s) : Etoricoxib
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Sponsor : Equilab International
Deal Size : Inapplicable
Deal Type : Inapplicable